We are no longer accepting Actos cases.
Exhibit 26 is a sales team power point presentation for Takeda sales reps attending an American Diabetic Association conference for health care professionals (HCPs). The 9th page of the document (p. 12 of the linked PDF file) shows a “Sales Force Verbatim” that explains what to tell physicians attending the conference about the Actos bladder cancer issue. “Please wait for HCPs to ask the question before using the verbatim. If no questions/concerns, do not discuss bladder cancer and sell, sell, sell!”
The sales representatives were also given guidance as to what they should say if the bladder cancer issue was raised (p. 18 of the linked PDF file). Takeda offered the follow suggested patter:
Dr., [thank you for asking.] As you may be aware, in an update to its ongoing safety review the FDA has informed the public that “... use of ACTOS for more than one year may be associated with an increased risk of bladder cancer. "
The implications of the document for jurors were clear. Takeda had vital information that any patient or doctor would clearly want to know. But Takeda instructed its sales force to withhold that information unless their hand was forced.
Return to Unsealed Actos Trial Documents Reveal Takeda Plan to Deceive Physicians and Consumers
|
